Inovio Pharmaceuticals (INO) Accumulated Expenses (2010 - 2026)

Inovio Pharmaceuticals has reported Accumulated Expenses for 17 years, with the latest figure at $817331.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 55.07% year-over-year to $817331.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $817331.0 (down 55.07% YoY) and the FY2025 annual result came in at $650680.0, down 67.82% from the prior year.
• Accumulated Expenses climbed to $817331.0 in Q1 2026 per INO's latest filing, from $650680.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $13.5 million in Q3 2022 and troughed at $650680.0 in Q4 2025.
• A 5-year average of $5.1 million and a median of $4.5 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses soared 60.47% in 2022, then slumped 78.74% in 2025.
• Over 5 years, Accumulated Expenses stood at $10.6 million in 2022, then tumbled by 77.67% to $2.4 million in 2023, then decreased by 14.52% to $2.0 million in 2024, then plunged by 67.82% to $650680.0 in 2025, then climbed by 25.61% to $817331.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $817331.0, $650680.0, and $955970.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.